RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19) Save

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.

1. "People don't believe what you tell them. They rarely believe what you show them. They often believe what their friends tell them. They always believe what they tell themselves." - SETH GODIN 
2. 142 pts with ANCA-Associated Vasculitis were studied for lipid levels - Lipid levels increased during remission in newly diagnosed AAV and PR3+ AAV (not MPO or relapsing pts). Lipid levels correlated w/ ESR but not other inflammatory markers. https://t.co/9UgUXv6BhI
3. 41 participants with RA and T2D were randomised to recv anakinra or a TNFi; RA dz activity decreased in both groups over 6 mos. Anakinra significantly improved A1C at 3 and 6 mos, but TNFi did not. https://t.co/UIBsRjMbKR
4. Systemic sclerosis is associated with an increased cancer risk. A cohort of 1727 SSc pts showed an increased cancer SIR of 2.15 (CI 1.84‐2.49). Most common cancers were breast, melanoma, hematological & lung. CA risk higher w/ RNAP III Ab, CCB Rx & ILD https://t.co/q5iTRI91Ng
5. Renal Review on treating asymptomatic hyperuricemia in CKD patients finds very few studies demonstrating renal protective effects w/ ULT w/ an abnormal uric acid. (this is without consideration of degree of CKD or hyperuricemia) https://t.co/nKo018lb6v
6. Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
7. MMWR: Increased Opioid Use in Lupus    
8. Low Dose IL-2 Effective in Lupus     
9. Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors